Tuesday May 14
Ironwood Pharmaceuticals and Forest Laboratories, Inc. to Present Linaclotide Data at
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Ironwood Pharmaceuticals, Inc.
Mon May 13, 2013
Forest Laboratories Coverage Initiated at BMO Capital Markets
The firm issued an underperform rating and a $27.00 target price on the stock. Shares of Forest Laboratories opened at 38.11 on Thursday.
Fri May 10, 2013
Analyst Moves: MU, FRX, AES, CVC
This morning, JMP downgraded shares of Micron from outperform to market perform citing valuation.
Today's Research on DCTH, AKRX, ASTX, BMRN, and FRX
StockCall.com Provides Stock Research on Delcath Systems Inc., Akorn Inc., Astex Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., and Forest Laboratories Inc.
Thu May 09, 2013
Trevena Inc. and Forest Laboratories Announce a Collaborative...
KING OF PRUSSIA, Pa. & NEW YORK -- -- Trevena Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptors biased ligands, and Forest Laboratories Holding Limited , a subsidiary of Forest Laboratories, Inc.
Wed May 08, 2013
Ferrex PLC Given Corporate Rating at FinnCap
's stock had its "corporate" rating reaffirmed by FinnCap in a research note issued on Wednesday, Analyst Ratings Network.com reports.
Sun May 05, 2013
GlaxoSmithKline plc (ADR) (GSK), Theravance Inc (THRX): Take a Deep...
Every Sunday I make it a point to examine a combination of earnings stories or Food and Drug Administration panel reviews or PDUFA decisions in the upcoming week that you can't afford to miss.
Sat May 04, 2013
Second Phase III Study For Aclidinium And Formoterol Combination In COPD Produces Positive Results
Aclidinium/formoterol demonstrates consistent, statistically significant lung function improvement in the second pivotal efficacy trial.
Thu May 02, 2013
Forest Laboratories Rating Reiterated by Barclays Capital
's stock had its "equal weight" rating reaffirmed by Barclays Capital in a research note issued on Thursday, Analyst Ratings.Net reports.
Globe and Mail
Almirall, Forest to seek approval for inhaler drug in US, Europe
ROB Insight is The Globe and Mail's exclusive feature led by a team of award-winning editors and writers who provide you with in-depth analysis on breaking business news and the issues that matter most.
Wed May 01, 2013
Customer Interaction Solutions
Forest Laboratories and Almirall Announce Positive Results for the...
Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate , delivered in the Pressair inhaler.
Sun Apr 28, 2013
Forest Laboratories's "Hold" Rating Reaffirmed at Deutsche Bank
's stock had its "hold" rating reiterated by equities research analysts at Deutsche Bank in a research note issued to investors on Wednesday, StocKRatingsNetwork.com reports.
Wed Apr 24, 2013
Forest Laboratories Rating Reiterated by Zacks
's stock had its "neutral" rating restated by Zacks in a research report issued to clients and investors on Wednesday, AnalystRatingsNetwork.com reports.
Tue Apr 23, 2013
Ironwood Pharma skids following 1st-quarter report Shares of Ironwood ...
THE SPARK: The Cambridge, Mass., company reported a bigger loss and less revenue than analysts expected.
Forest Laboratories Management Discusses Q4 2013 Results - Earnings Call Transcript
Francis I. Perier - Chief Financial Officer, Executive Vice President of Finance & Administration and Member of Disclosure, Legal Compliance & Risk Management Committee Marco Taglietti - Senior Vice President of Research & Development, Member of Disclosure, Legal Compliance & Risk Management Committee and President of Forest Research Institute Good ... (more)
Forest Laboratories (FRX) Announces Quarterly Results
Forest Laboratories issued its quarterly earnings data on Tuesday. The company reported $0.17 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.16 by $0.01, Analyst Ratings.Net reports.
Forest Laboratories (FRX) Releases FY14 Earnings Guidance
Forest Laboratories issued an update on its FY14 earnings guidance on Tuesday morning.
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013...
Forest Laboratories, Inc. , an international pharmaceutical manufacturer and marketer, today announced that reported diluted earnings per share equaled $0.17 in the fourth quarter of fiscal 2013.